World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
34804
World Ranking
15890
National Ranking
7994

Overview

Gregory A. Otterson is affiliated with The Ohio State University in the United States. Their research primarily focuses on medicine, with a significant emphasis on oncology. Within this broad field, their work spans subfields including oncology, pulmonary and respiratory medicine, epidemiology, molecular biology, and radiology, nuclear medicine, and imaging.

They have contributed notably to multiple topics within cancer research. These topics encompass cancer immunotherapy and biomarkers, lung cancer treatments and mutations, lung cancer research studies, colorectal cancer treatments and studies, lung cancer diagnosis and treatment, pancreatic and hepatic oncology research, and inflammatory biomarkers in disease prognosis.

Otterson's publication record features numerous articles in a variety of respected journals. Frequent venues for their work include:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Journal of the National Comprehensive Cancer Network
  • Cancer Immunology Immunotherapy
  • Clinical Lung Cancer

Notable papers authored or co-authored by Otterson include:

  • Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021, 2021, Journal of the National Comprehensive Cancer Network
  • Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer, 2020, JAMA Oncology
  • NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023, 2023, Journal of the National Comprehensive Cancer Network
  • Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration, 2020, Nature Medicine

Frequent collaborators in Otterson's research include Dwight H. Owen, Carolyn J. Presley, David P. Carbone, Lai Wei, and Mingjia Li. These co-authorships reflect sustained partnerships within the field of oncology.

Best Publications

  • Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    Matthew D. Hellmann;Tudor-Eliade Ciuleanu;Adam Pluzanski;Jong Seok Lee

  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

  • Non–Small Cell Lung Cancer

    David S. Ettinger;Wallace Akerley;Gerold Bepler;Andrew Chang

  • Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology

    David S. Ettinger;Douglas E. Wood;Dara L. Aisner;Wallace Akerley

  • Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines

    David S. Ettinger;Douglas E. Wood;Charu Aggarwal;Dara L. Aisner

  • NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

    David S. Ettinger;David S. Ettinger;Douglas E. Wood;Douglas E. Wood;Dara L. Aisner;Wallace Akerley;Wallace Akerley

  • Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

    Jacob J. Chabon;Andrew D. Simmons;Alexander F. Lovejoy;Mohammad S. Esfahani

  • Non-small cell lung cancer: Clinical practice guidelines in oncology

    David S. Ettinger;Wallace Akerley;Gerold Bepler;Matthew G. Blum

  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

    Roy S Herbst;Rafat Ansari;Frederique Bustin;Patrick Flynn

  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

    Neal Ready;Matthew D. Hellmann;Mark M. Awad;Gregory A. Otterson

  • Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines

    David S. Ettinger;Wallace Akerley;Hossein Borghaei;Andrew C. Chang

  • Non–Small Cell Lung Cancer, Version 6.2015

    David S. Ettinger;Douglas E. Wood;Wallace Akerley;Lyudmila A. Bazhenova

  • NCCN Guidelines ® Insights: Non-Small Cell Lung Cancer, Version 4.2016 Featured Updates to the NCCN Guidelines

    David S. Ettinger;Douglas E. Wood;Wallace Akerley;Lyudmila A. Bazhenova

  • Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.

    Samir N. Khleif;James Degregori;Carole L. Yee;Gregory A. Otterson

  • NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

    David S. Ettinger;Dara L. Aisner;Douglas E. Wood;Wallace Akerley

  • Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth

    William R. Sellers;Bennett G. Novitch;Satoshi Miyake;Agnieszka Heith

  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

    Alexander Drilon;Alexander Drilon;Salvatore Siena;Rafal Dziadziuszko;Fabrice Barlesi

  • MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines.

    M. Crawford;E. Brawner;K. Batte;L. Yu

  • Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).

    Ying Zhao;Shaoli Lu;Lipeng Wu;Guolin Chai

  • Malignant pleural mesothelioma.

    David S. Ettinger;Wallace Akerley;Hossein Borghaei;Andrew Chang

Frequent Co-Authors

David P. Carbone
David P. Carbone The Ohio State University
David S. Ettinger
David S. Ettinger Johns Hopkins University
Leora Horn
Leora Horn Vanderbilt University Medical Center
Thomas A. D'Amico
Thomas A. D'Amico Duke University
Peter G. Shields
Peter G. Shields The Ohio State University
Ramaswamy Govindan
Ramaswamy Govindan Washington University in St. Louis
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Wei-Guo Zhu
Wei-Guo Zhu Shenzhen University
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering the broader healthcare field beyond traditional medical degrees, there are several flexible online options to launch or advance your career. Programs like direct entry msn online allow non-nurses to quickly transition into advanced nursing roles, offering an efficient path for career changers. Those looking for more accessible entry points might also explore direct entry nursing programs with fewer prerequisites and a streamlined admissions process.

Allied health careers such as medical billing and coding offer solid job prospects and can be pursued from home. Consider some of the best online medical billing and coding schools if you prefer a non-clinical healthcare role with flexible learning options.

Finally, if standardized testing poses a challenge, certain absn programs that don't require teas can help you bypass some common entrance exams, making the path to a nursing degree more accessible.

Best Scientists Citing Gregory A. Otterson

Trending Scientists

Recently Published Articles